LI-RADS TRA v2024 succeeds where RECIST and mRECIST fail: viability-based survival prediction in TACE-treated hepatocellular carcinoma
Abdominal Radiology · 2026
DOI: 10.1007/s00261-026-05556-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Abdominal Radiology, 2026. Verfasst von Alisa Mohebbi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Tomography, X-Ray Computed. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Despite robust response assessment validation of Liver Imaging Reporting and Data System Treatment Response Algorithm (LI-RADS TRA) version 2024, a critical evidence gap exists for its prognostic value in non-radiation hepatocellular carcinoma (HCC) therapies. Conventional response assessment criteria (RECIST, mRECIST) focus on morphologic changes, not tumor viability. PURPOSE: To evaluate the prognostic implications of LI-RADS TRA v2024 versus RECIST and mRECIST for predicting overall survival and time to progression in HCC patients treated with trans-arterial chemoembolization (TACE), and to assess whether quantitative enhancement reduction augments prognostic stratification. METHODS: A total of 105 HCC patients undergoing TACE with multi-phasic contrast-enhanced CT were included. Four board-certified radiologists independently assessed tumor response using LI-RADS TRA v2024, RECIST, and mRECIST criteria. RESULTS: LI-RADS TRA demonstrated convergent prognostic discrimination for overall survival, with non-responders achieving mean survival of 719.8 days versus responders 1,002.1 days (p = 0.014; hazard ratio 1.63). In contrast, RECIST (p = 0.670, hazard ratio 0.72) and mRECIST (p = 0.457, hazard ratio 1.16) showed negligible stratification. Importantly, LI-RADS TRA exhibited weak discrimination for time to progression (p = 0.095). Incorporating quantitative enhancement-size change from pre-TACE to post-TACE (%) substantially enhanced LI-RADS TRA prognostic performance for survival (HR 1.91, p = 0.026), but not progression prediction. CONCLUSION: LI-RADS TRA v2024 outperforms conventional size-based and enhancement-duration criteria for mortality risk stratification in TACE-treated HCC, reflecting mechanistic potential of viability-based assessment. However, imaging response predicts cumulative mortality, not progression timing. Integration of quantitative enhancement metrics refines risk stratification for surveillance planning.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran.
- Urmia University of Medical Sciences, Urmia, Islamic Republic of Iran.
- Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran. Pakneda@yahoo.com.
Zitieren
APA
Mohebbi, A., Zare, M., Mohammadi, A., & Pak, N. (2026). LI-RADS TRA v2024 succeeds where RECIST and mRECIST fail: viability-based survival prediction in TACE-treated hepatocellular carcinoma. Abdominal Radiology. https://doi.org/10.1007/s00261-026-05556-4
Vancouver
Mohebbi A, Zare M, Mohammadi A, Pak N. LI-RADS TRA v2024 succeeds where RECIST and mRECIST fail: viability-based survival prediction in TACE-treated hepatocellular carcinoma. Abdominal Radiology. 2026. doi:10.1007/s00261-026-05556-4
BibTeX
@article{Mohebbi2026,
author = {Mohebbi, Alisa and Zare, Mehrad and Mohammadi, Afshin and Pak, Neda},
title = {LI-RADS TRA v2024 succeeds where RECIST and mRECIST fail: viability-based survival prediction in TACE-treated hepatocellular carcinoma},
journal = {Abdominal Radiology},
year = {2026},
doi = {10.1007/s00261-026-05556-4}
}
EUVIMED